Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Net Cash Flow (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Net Cash Flow for 11 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 16.61% year-over-year to $20.8 million, compared with a TTM value of -$3.7 million through Dec 2025, up 96.29%, and an annual FY2025 reading of -$3.7 million, up 96.29% over the prior year.
  • Net Cash Flow was $20.8 million for Q4 2025 at Spyre Therapeutics, up from -$16.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $200.1 million in Q2 2023 and bottomed at -$182.4 million in Q2 2024.
  • Average Net Cash Flow over 5 years is -$305850.0, with a median of -$183000.0 recorded in 2022.
  • The sharpest move saw Net Cash Flow tumbled 11226.75% in 2023, then surged 30582.54% in 2024.
  • Year by year, Net Cash Flow stood at -$9.5 million in 2021, then skyrocketed by 56.45% to -$4.1 million in 2022, then skyrocketed by 2445.66% to $97.3 million in 2023, then crashed by 81.65% to $17.9 million in 2024, then increased by 16.61% to $20.8 million in 2025.
  • Business Quant data shows Net Cash Flow for SYRE at $20.8 million in Q4 2025, -$16.8 million in Q3 2025, and $33.2 million in Q2 2025.